Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer

• Published in: Trends in Immunotherapy Vol. 6; no. 1
• Main Authors: Nomizo, Takashi, Yamamoto, Haruka, Murayama, Tsunetaka, Fukata, Hiroko, Nakamura, Yasukiyo, Sonomura, Mami, Okuno, Aika, Kanda, Naoki, Watanabe, Chihiro, Kita, Hideo
• Format: Journal Article
• Language: English
• Published: 14.01.2022
• ISSN: 2573-5985; 2573-5985
• DOI: 10.24294/ti.v6.i1.1386

It has been less than a decade since immune checkpoint inhibitors became the mainstay of lung cancer treatment, and 2020 saw the advent of the era of complex immune checkpoint inhibitors. Although clinical trials have shown that the therapeutic effects of complex immune checkpoint inhibitors are favorable, they are associated with an increase in adverse events. The use of combined immune checkpoint inhibitors in clinical practice has progressed slowly, and the frequency and types of adverse events they cause remain unclear. Here we report the adverse events of six patients with lung cancer treated with regimens containing nivolumab and ipilimumab in 2021. Four of the six patients had grade 3 or higher adverse events, including one patient with lung injury and one patient with skin injury, both of whom died. The timing and nature of the adverse events were difficult to predict.